Precision Biosciences (DTIL) Capital Expenditures (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Capital Expenditures of $18000.0 for Q1 2026, down 71.88% year-over-year from $64000.0 in Q1 2025, and down 5.26% quarter-over-quarter from $19000.0 in Q4 2025.
Precision Biosciences (DTIL) Capital Expenditures (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Capital Expenditures for 9 consecutive years, with $18000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 71.88% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $39000.0 (down 82.89% YoY), while the FY2025 annual figure was $85000.0, down 66.0% from the prior year.
- Capital Expenditures retreated to $18000.0 in Q1 2026 per DTIL's latest filing, from $19000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.1 million in Q3 2022 and bottomed at -$26000.0 in Q4 2023.
- Historically, Capital Expenditures has averaged $351812.5 across 5 years, with a median of $91500.0 in 2024.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 104.11% — and 2024, when it surged 473.08%.
- Precision Biosciences' Capital Expenditures stood at $632000.0 in 2022, then slumped by 104.11% to -$26000.0 in 2023, then soared by 473.08% to $97000.0 in 2024, then sank by 80.41% to $19000.0 in 2025, then decreased by 5.26% to $18000.0 in 2026.
- Business Quant data shows DTIL's Capital Expenditures at $18000.0 in Q1 2026, $19000.0 in Q4 2025, and $2000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | 39,000.00 |
| Sep 30, 2024 | 39,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Sep 30, 2023 | 386,000.00 |
| Sep 30, 2023 | 386,000.00 |